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Available online 25 March 2014AbstractBackground/Aims: To study the in vitro antibacterial activity of methanolic leaf extract of Combretum albidum in combination with the antibiotic
ceftriaxone (CE) against multidrug-resistant (MDR) Pseudomonas aeruginosa, and to assess the host toxicity of the leaf extract with human cord
blood-derived lymphocytes in vitro.
Methods: The synergistic/antagonistic action of the leaf extract with CE was evaluated with the checkerboard procedure. The leaf extract and the
antibiotic were added into the wells of a microtiter plate in serially proportionate combinations along with nutrient broth, bacterial inocula, and
2,3,5-triphenyltetrazolium chloride to achieve visible growth of the bacterium. Lymphocytes from human cord blood were cultured and the
toxicity of the leaf extract was assessed by both acridine orange/ethidium bromide (AO/EB) staining method and 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay. The test results were analyzed by the probit method.
Results: Minimum inhibitory concentration (MIC) values of the methanolic leaf extract and CE separately were 0.866 and 0.0384 mg/mL,
respectively. The MIC value of the leaf extract with the antibiotic was in the range of 0.102e0.866 mg/mL. Synergistic results in the in vitro
control were obtained in all combinations of the antibiotic and the extract (i.e., from 9:1 to 5:5); ratios 1:9, 2:8, and 3:7 caused antagonism,
whereas an indifference was seen at the ratio 4:6. Individual minimum bactericidal concentration (MBC) values of the leaf extract and CE were
4.39 and 87.7 mg/mL, respectively, whereas those of all combinations, 9:1 to 1:9, ranged from 0.33 to 3.07 mg/mL. The MBC value of the leaf
extract alone was 4.39 mg/mL, whereas in various combinations with CE (at ratios from 9:1 to 1:9), the value varied from 0.70 to 3.07 mg/mL.
The MBC value of CE was only 0.877 mg/mL in all combinations with the leaf extract. The plant extract level of 58.88 mg/mL was considered
the lethal concentration 25 (LC25) because of its lethal effects on lymphocytes, whereas the LC25 value for CE was 380.19 mg/mL according to
the AO/EB staining method. In the MTT assay, however, the LC25 value of leaf extract was 53.70 mg/mL. Therefore, we used a leaf extract
concentration of 50 mg/mL, which was a little below the LC25 value of leaf extract obtained in the MTT assay (i.e., 53.70 mg/mL).
Conclusion: This study provided the result of synergistic activity of the combination of crude leaf extract of C. albidum with CE against MDR
P. aeruginosa. The leaf extract was nontoxic to human lymphocytes.
Copyright  2014, Taiwan Society of Emergency Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
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nation therapy has been applauded amply and embroiled in the
effective control module for the prevention of an infection
after a surgical episode, at levels far below their individual
host-toxicity levels to prevent the emergence of intriguing
multidrug-resistant (MDR) pathogenic bacterial strains.2,3
Indeed, drugs/antibiotics used in combination therapy
involve interactions that could be antagonistic, indifferent/
additive, or synergistic. Antagonism is defined as a scenario in
which a combination of drugs is less effective than the single
agents on a target organism. An example of such a situation
could be an interaction of one or two bacteriostatic drugs, such
as a protein synthesis inhibitor, chloramphenicol, or tetracy-
cline, with penicillin or/and an aminoglycoside.4 Obviously,
while using multiple drugs/antibiotics in a therapy, better
outcomes are achieved with fewer encumbrances. Indifferent/
additive effect is a combined action equivalent to the sum of
actions of individual drugs used.5 Synergism is a situation in
which the combined effect is significantly or inimitably better
than the sum of individual effects of the drugs used,6 which is
unequivocally desired in antimicrobial stewardship programs.
Nowadays, there is more focus on the search for effective/new
antimicrobials because of the recent need to control MDR
pathogenic bacteria.7 Plant-based antimicrobial drugs are
widely investigated and they remain as potential sources of
antimicrobials for the control of both bacteria and fungi.8e11
Indeed, the search for complementary and alternate thera-
peutics becomes an obsessive quest, and phytodrugs remain an
exploitable and readily available source for the in vitro control
of a series of MDR pathogens, which are repeatedly controlled
with crude phytodrugs.12e14 Because phytocompounds in
crude plant extracts have inherently unbreachable barriers of
complexity and are of nonmicrobial origin, no MDR microbes,
including those with unique genetic makeups, could ever
override these coalesced chemicals. If scaled up in a module,
accessorized with the formal antimicrobial stewardship pro-
gram, phytocompounds of suitable plants could be used as
complementary and alternate medicines, rather than integra-
tive medicines, such as mixing allopathic/mainstream and
herbal medicines.15e19 Basic information on herbal drugs is
obtained from folklore literature of different cultures world-
wide. By contrast, many antibiotics that became a routine
against one or the other class of pathogen with a proven
exquisite control capacity cannot ordinarily be replaced by a
newer drug because of its recent failure in controlling an
affronting MDR pathogen, nor the rising mortality rates can be
assumed to be arising out of treatment failures. Moreover, an
antibiotic at a specified dose that has been won over by a strain
of a bacterium may control the resistant strain, when used at a
higher dose. However, the same antibiotic at a comparatively
higher dose would be toxic to the host organism. Thus, the
most sought after blithesome situation would be the use of a
new agent having a synergistic effect with a moribund
antibiotic.
The in vitro interaction of two control agents could be
monitored with a checkerboard and the time killer method
alternately.20 The former method involves the determination ofpercentage growth inhibition of the targeted bacterium in vitro
in the presence of two drugs at different combinations. This is
a simple method and the results can be easily interpreted.21
Such antibacterial results are interpreted as fractional inhibi-
tory concentration (FIC) index ¼ FICA þ FICB ¼ MICA, in
combination/MICA tested alone þ MICB in combination/
MICB tested alone,
22 where MICA and MICB are the minimum
inhibitory concentration (MIC) values of drugs A and B,
respectively. The MDR Pseudomonas aeruginosa, which
showed resistance to 15 antibiotics in this hospital recently,
had been the most notorious pathogen,23 causing infections at
the urinary and respiratory tracts as well as at surgical/burn
sites. Most of its strains were resistant to 30 mg/disc ceftri-
axone (CE), which is the recommended dose in therapy.
However, higher doses of CE would probably be effective in
the control of P. aeruginosa, but at the same time could trigger
many side effects, including diarrhea, nausea, vomiting, sto-
matitis, glossitis, hemolytic anemia, thrombocytopenia, exan-
thema, allergic dermatitis, pruritus, urticaria, and edema, etc.24
Furthermore, leaves of the medicinal plant Combretum
albidum G. Don are used in treating patients with jaundice and
its bark is used for treating various skin diseases.25 A decoc-
tion of the fruit is used for treating dysentery and diarrhoea.26
Thus, C. albidum has an established record of ethnobotanical
image, without any known host toxicity. Its bark extract also
has liver-protective effects.27 In this study, the interaction
between the methanolic leaf extract of C. albidum and CE (a
third-generation cephalosporin), which was ineffective at the
recommended concentration against a great proportion of an
MDR strain of P. aeruginosa isolated from clinical samples,
had been monitored with the checkerboard method. The re-
sults obtained provide a rational base for the use of methanolic
leaf extract of C. albidum, which is used by an aborigine tribe
(the Kandha) of the local subtropical forest, and the moribund
antibiotic CE (often used in empirical therapy for at least the
control of respiratory ailments and untoward suppurations) in
different combinations of each control agent against a CE-
resistant P. aeruginosa strain, which is resistant to several
other antibiotics concomitantly in vitro, with the hope of
achieving a desirable synergistic effect.
Logistically, monitoring host toxicity of the used antimi-
crobial agent is an essential corollary, regardless of its sour-
cedmicrobial or botanical or synthetic. Indeed, the host
toxicity is monitored with experimental animals, which in-
volves many tedious procedures. By contrast, stem cells/
lymphocytes from the umbilical cord blood (UCB) could be
grown in vitro and used for testing the host toxicity. Obviously,
the use of whole animal for testing host toxicity would be the
ultimate practice before the use of a compound as a drug in
humans. The use of cultured human cells is not an ordinary
substitute, as it would give a chance for ascertaining the real
situation of toxicity more correctly instead of using small
experimental animals, such as mice; nonetheless, mammals
are used as test animals. It is anticipated that the work with
lymphocytes, especially from the human UCB, has neither the
linked problems of involvement of trials with animals nor is an
ethically sensitive issue, as it is a waste blood. Using
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mirror of events in the human body. The host toxicity in this
case is monitored using cultured lymphocytes, which are ob-
tained from human cord blood and this study gives a
comparative account of toxicity levels of the antibiotic CE as
well as the crude leaf extract of the medicinal plant C.
albidum.
2. Materials and methods2.1. Preparations of plant extractsLeaves of C. albidum G. Don (Family: Combretaceae) were
dried at 37C for 24 hours in an incubator andwere further shade
dried for 15 days. Dried leaveswere powdered and the powdered
mass was stored in air-tight polythene packs until further use.
The methanolic extraction of leaves was carried out in a Soxhlet
apparatus by mixing a series of 40 g of powdered mass with
400 mL of methanol for 24 hours; about 40 extracted units were
obtained.After filtration, the extractwas concentrated in a rotary
evaporator. The sticky mass obtained was dried in a desiccator
and a black solid mass was obtained, which was stored in a
suitable volume of 10% dimethyl sulfoxide (DMSO) at the
concentration of 50 mg/mL at 4C until use. The yield of the
solid mass was determined as 7.92%.2.2. Screening of phytochemicalsThe methanolic leaf extract was subjected to different tests
in preliminary screening protocols for 17 active phytochemical
constituents.28e30 Qualitative phytochemical analyses of the
plant extract for nine phytochemicals, namely, alkaloids, fla-
vonoids, saponins, resins, steroids, tannins, glycosides,
reducing sugars, and anthraquinones, were performed as
described previously.13 The additional eight phytochemi-
calsdphlobatannins, sterols, lipids/fats, acidic compounds,
terpenoids, phenols, carbohydrates, and catecholdwere tested
as follows:
 Phlobatannins: A few drops of 1% HCl were added to the
mixture of 0.5 g leaf extract in a tube with water in boiling
state. The mixture was allowed to stand for the develop-
ment of a red precipitate, which confirms the presence of
phlobatannins.
 Sterols (LiebermanneBurchard test): A lot of 0.5 g leaf
extract was dissolved in an aliquot of 3.0 mL chloroform
and a few drops of acetic anhydride were added along with
a few drops of concentrated sulfuric acid (H2SO4) along
the sides of the test tube. Formation of a blue to blood red
color confirms sterol.
 Lipids/fats: A small quantity of the powdered leaf extract
was rubbed onto a filter paper. Appearance of a permanent
translucent strain confirms lipids/fats.
 Acidic compounds: To a little amount of the extract, an
aliquot of 1 mL of 4% sodium bicarbonate solution was
added for effervescence to confirm the presence of acidic
compounds. Terpenoids (Salkowski’s test): To a lot of 0.5 g of the
extract, an aliquot of 2 mL of chloroform was added,
followed by an addition of concentrated H2SO4 (3 mL) to
form a layer. A reddish brown color formation at the
interface was noted, which confirms the presence of
terpenoids.
 Phenols: A little amount of the extract was diluted with
water to which an aliquot of 2 mL of 1% ferric chloride
solution was added for the formation of green or blue
color, which confirms the presence of phenol.
 Carbohydrates (Molisch’s test): A small quantity of the
extract was dissolved in an aliquot of 5 mL of distilled
water and filtered. To this filtrate, two to three drops of a-
naphthol were added. In addition, an aliquot of 1 mL of
concentrated H2SO4 was added; two layers were formed
with a violet-colored ring at the interface, which confirms
the presence of carbohydrates.
 Catechol: To 2 g of the extract, 2 mL of freshly prepared
Ehrlich’s reagent was added along with a few drops of
concentrated HCl. Formation of a black precipitate con-
firms the presence of catechol.2.3. Isolation and identification of the bacteriumStrains of P. aeruginosawere isolated from clinical samples.
Urine samples from patients with urinary tract infections were
cultured on nutrient agar, for 18e24 hours, for the isolation of
bacterial strains. Nonlactose fermenting, colorless colonies on
MacConkey agar that also formed green-pigmented colonies on
further streaking on nutrient agar (HiMedia, Mumbai, India)
were tested for P. aeruginosa. These green-pigmented colonies
inhibited the growth of other bacteria around them, and were
confirmed as Gram-negative bacilli. P. aeruginosa were iden-
tified with specific biochemical tests. To confirm that P. aeru-
ginosa colonies are obtained only from clinical samples and not
from any nosocomial infection/contamination, many clinical
samples were repeatedly plated. Isolated cells of P. aeruginosa
were slender, noncapsulated with a polar flagellum. Confirma-
tory biochemical tests carried out included the catalase test, the
oxidase test, and the growth of colonies in King’s media, as
described previously.14,23 The colonies were positive for oxi-
dase, catalase, citrate, urease, and nitrate tests, whereas they
were negative for indole, methyl red, and VogeseProskauer
tests. When the colonies were further grown in King’s B agar
medium, fluorescein (pyoverdine) imparting a yellow tinge to
the culture was observed and the colored material was insoluble
in chloroform but soluble in water; some colonies developed
bright red and water-soluble pyorubin. No pyomelanin, a brown
to black pigment, was seen in any of the King’s media. These
tests confirmed the isolation of strains of P. aeruginosa.232.4. Antibiotic-sensitivity pattern of isolated P.
aeruginosaThe disc diffusion method was used for the antibiotic-
sensitivity test, using a 4-mm-thick MuellereHinton agar
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of P. aeruginosa were obtained and each strain was subjected
to antibiotic-sensitivity test, using 17 antibiotics belonging to
five groups, and one of the MDR strains that was resistant to
CE 30 mg/disc was used for further study.2.5. Determination of MIC and minimum bactericidal
concentration values of the leaf extract and CEA powdered form (injectable) of the antibiotic CE was
dissolved in an appropriate volume of water to prepare a stock
solution of 1 mg/mL. The concentration of the plant extract
was 50 mg/mL. The sensitivities of P. aeruginosa to the
methanolic leaf extract and CE were evaluated by determining
the MIC values. Serial dilutions of the methanolic extract were
added in succession to wells on a row in a 96-well (12  8)
microtiter plate (Fig. 1). An 80 mL aliquot of the leaf extract
was added to the first well with a 100 mL aliquot of nutrient
broth (HiMedia). From the first well, an aliquot of 80 mL was
drawn and transferred to the second well containing 100 mL of
nutrient broth. The remaining wells received 80 mL content of
the previous well, in succession for the total of 11 wells; an
aliquot of 20 mL bacterial inoculum (106 CFU/mL) and 5 mL
aliquot of 0.5% of 2,3,5-triphenyltetrazolium chloride (TTC)
were added to each well. The l2th well did not receive the plant
extract and served as the control. After adding all of the
aforementioned constituents to each well, the microtiter plate
was incubated at 37C for 18 hours. A pink coloration owing
to the presence of TTC in a well indicated bacterial growth
and the absence of pink coloration was taken as growth inhi-
bition.13 The MIC (the lowest toxic concentration) value was
noted at the well with the lowest level, in which the pink color
was not manifested.32 Further, bacterial content from each
well of the microtiter plate was subcultured on nutrient agar
plates; from previously ascertained MIC levels and above, the
level of dilution, with which no bacterial growth on the
nutrient agar plate was observed, was noted as the minimum
bactericidal concentration (MBC) value (Fig. 2). This methodFig. 1. Minimum inhibitory concentrations (MICs) of different combinations
of Combretum albidum crude leaf extract and ceftriaxone. M ¼ MIC at
numbers that signify ratios of leaf extract:ceftriaxone (1 ¼ 10:0, 2 ¼ 9:1,
3 ¼ 8:2, 4 ¼ 7:3, 5 ¼ 6:4, 6 ¼ 5:5, 7 ¼ 4:6, 8 ¼ 3:7).was repeated to determine the MIC and MBC values of the
antibiotic.2.6. Checkerboard technique for combination activity of
leaf extract and CETo evaluate the synergistic/antagonistic interaction of the
leaf extract with CE, the checkerboard procedure was used.33
In this method, the leaf extract and the antibiotic were added
into the wells of the microtiter plate (Fig. 1) in serially pro-
portionate combinations along with nutrient broth, bacterial
(an MDR strain) inocula, and TTC for the visible growth of the
bacterium. The combinations of leaf extract and CE were
prepared in the following proportions: 10:0, 9:1, 8:2, 7:3, 6:4,
5:5, 4:6, 3:7, 2:8, 1:9, and 0:10. Each proportion was adjusted
to 1.0 mL in an Eppendorf tube. The solution in each tube was
serially dispensed to a row of 11 wells in the microtiter plate.
Finally, each well had an aliquot of 100 mL of nutrient broth,
20 mL aliquot of bacterial inoculum, and 5 mL aliquot of TTC,
for the growth of the bacterium. The combinations were
checked for MIC and MBC values with the antibiotic, as
described earlier. Interaction was assessed algebraically by
determining the FIC indices (FIC index ¼ FIC of
extract þ FIC of CE). In addition, fractional bactericidal
concentration (FBC) indices for both the leaf extract and the
antibiotic were computed. The FIC index was interpreted as
(1) a synergistic effect, when it was lesser than 0.5; (2) an
additive or indifferent effect, when it was more than 0.5 and
lesser than 1; and (3) an antagonistic effect, when it was more
than 1.0.34Fig. 2. The zone marked as 6 shows the minimum bactericidal concentration
(MBC) value. Zones 7 and 8 were with growing bacteria. Zones 1e5 had
bacterial levels higher than the MBC. Zones 1e8 contained inocula of the first
eight wells in the 5:5 combination ratio, or the sixth combination pair shown in
Fig. 1.
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extract of C. albidumThe inhibition zone (IZ) of the methanolic leaf extract of C.
albidum against P. aeruginosa was determined by the agar cup
method.35 Inocula from an overnight nutrient broth culture of
P. aeruginosa were firmly seeded over the MHA plates. The
scooped out wells on agar plates were sealed by pouring 50-
mL molten MHA. Aliquots of 100 mL leaf extract in twofold
decreasing concentrations were poured into the wells of the
plate. The plates were incubated at 37C for 24 hours and the
sizes of IZs around the wells were noted.2.8. Separation of lymphocytes from cord bloodFig. 3. Density-gradient centrifugation of umbilical cord blood with
phosphate-buffered saline (PBS) solution. LSM ¼ lymphocyte separating
medium; RBC ¼ red blood cell.UCB was collected in a sterile 50-mL falcon tube (Tarsons,
Kolkata, India) containing 500 mL of 1000 IU heparin
(HiMedia). The UCB that was collected immediately after the
delivery of an infant, and the blood sample (50 mL) was stored
at 4C until use. Lymphocytes were isolated immediately or
within 24 hours after the collection. For the isolation of
lymphocytes, the collected UCB sample was diluted with an
equal volume of phosphate-buffered saline (PBS) solution.
The mixture was carefully loaded for overlayering into a
centrifuge tube with lymphocyte separating medium (LSM;
HiMedia), which was one-third the total volume of the
mixture. The total mixture was then centrifuged at 1800g for
25 minutes at 22e24C. The buffy coat with mononuclear
cells was carefully removed from the tube with layers. The
layers (heavy to light) obtained are red blood cell, LSM, buffy
coat, and plasma (Fig. 3). The cells of the buffy coat layer,
after dilution with another aliquot of PBS at the 1:1 ratio, were
recentrifuged at 2000g for 5 minutes. The lymphocytes pellets
were used for culturing, and the cell counts were measured
using a hemocytometer.2.9. Growth of lymphocytes and assessment of toxicity by
staining methodThe UCB-derived lymphocytes were diluted to the density
of 1  106 cells/mL with a required volume of Dulbecco’s
modified Eagle’s medium with low glucose (HiMedia), and
were loaded into a six-well culture plate (Tarsons), which
contained 15% fetal bovine serum (Sigma, Taufkirchen, Ger-
many), 1% penicillinestreptomycin, and 1% sodium pyruvate,
along with different concentrations of methanolic extract (50,
25, 12.5, 6.25, and 3.125 mg/mL) of C. albidum leaves with
10% DMSO solution and different concentrations (1000, 500,
250, 125, 62.5, and 31.25 mg/mL) of CE, for the growth of
UCB-derived lymphocytes. The stock solution of the C.
albidum leaf extract was prepared by dissolving 50 mg of
sticky methanolic leaf extract of the plant in a 1 mL aliquot of
10% DMSO solution, and the stock solution was stored at 4 C
for further use; the total volume of 2 mL was maintained for
each well of the culture plate with leaf extract. The cells were
incubated with different concentrations of the leaf extract (50,
25, 12.5, 6.25, 3.125, and 0 mg/mL) at 37C under 5%atmospheric CO2 concentration for 24 hours. Their viability
was investigated using the acridine orange/ethidium bromide
(AO/EB) staining under a fluorescent microscope (Magnus,
Noida, New Delhi, India). The AO/EB solution was prepared
in PBS at the concentration of 100 mg/mL. Green color indi-
cated live cells, whereas cells with orange and red color were
apoptotic and necrotic cells, respectively (Fig. 4). Toxicity
values were obtained with concentrations of 50, 25, 12.5, 6.25,
3.125, and 0 mg/mL methanolic leaf extract, after 24 hours of
incubation.
Percentages of lethality values of the third repeated
experiment were converted to probit values (Finney’s method),
which were plotted against the corresponding log10 values of
methanolic leaf extract and CE concentrations, as described
previously.36 The probit values of the observed lethality per-
centages are from statistical tables of probit transformations.372.10. 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assayYellow 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT), a tetrazole, is reduced to purple formazan in the
mitochondria of living cells. The solution is quantified by
measuring its absorbance at a wavelength between 500 and
600 nm using a spectrophotometer. The absorption maximum is
dependent on the solvent used. This reduction takes place only
when enzymes such as mitochondrial reductase are active, and
therefore, the conversion can be directly related to the number of
viable/living cells. The amount of purple formazan crystals
produced by the cells treated with a toxin is low as compared
with the amount of formazan crystals produced by the control
cells.
The cell toxicities of both leaf extract and CE were
assessed with the MTT assay; a stock of 5 mg/mL concen-
tration of MTT solution was prepared with PBS. After 24
hours of methanolic leaf extract/antibiotic treatment to lym-
phocytes in a six-well culture plate, 80 mL of MTT solution
Fig. 4. Acridine orange/ethidium bromide staining of in vitro grown lymphocytes in toxicity studies using Combretum albidum leaf extract and ceftriaxone. (A)
Control cells; (B) 3.125 mg/mL leaf extract; (C) 50 mg/mL leaf extract; (D) control cells; (E) 62.5 mg/mL ceftriaxone; (F) 1 mg/mL ceftriaxone.
Table 1
Antibiotic-sensitivity pattern of 51 strains of Pseudomonas aeruginosa by disc
diffusion method.
S. no. Antibiotic class Antibiotics IZ (mm) Result Percent
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plate was further kept in an incubator (37C, 5% CO2) for 4
hours. It was found that the media containing lymphocytes and
leaf extract/antibiotic manifested blue color due to the for-
mation of formazan crystals. After 4 hours of incubation, the
mixture was gently centrifuged at 1000g for 10 minutes at
22C. The supernatant was discarded and the pellet was dis-
solved in an aliquot of 1 mL of 100% DMSO solution and the
mixture was incubated at 37C for 1 hour. The blue color
becomes purple, after which the optical density at the 570 nm
was measured using a spectrophotometer. Percentage of cell
density is calculated as 100  (ODsample e OD blank)/ODcontrol;
MTT in the DMSO solution was the blank. Probits of the
observed lethality percentage values were used for analysis of
toxicity.
3. Results
(mg/disc) resistant
1 Aminoglycosides Amikacin 30 12 R 643.1. Interaction of plant extract with P. aeruginosa
Gentamicin 10 0 R 43
Netillin 30 10 R 51
Tobramycin 15 8 R 72
2 Beta-lactams Aztreonam 30 24 S 34
Piperacillin 100 0 R 42
Piperacillin/tazobactam
100/10
17 R 31
3 Cephalosporins Cefepime 30 19 S 90
Cefoperazone 75 14 R 62
Cefoperazone/sulbactam
50/50
24 S 44
Ceftazidime 30 0 R 25
Ceftriaxone 30 0 R 96
4 Carbapenem Imipenem 10 23 S 19
5 Fluoroquinolones Ciprofloxacin 5 14 R 60
Gatifloxacin 5 0 R 38
Levofloxacin 5 12 R 53
Ofloxacin 5 11 R 59
IZ ¼ inhibition zone; R ¼ resistant; S ¼ sensitive.Antibiotic-sensitivity test of 51 strains was performed. The
levels of resistance percentages were more than 50% in nine of
the 17 antibiotics tested, which clearly indicate the infection
dynamics of P. aeruginosa in community sectors and noso-
comial settings. Among the isolated strains, 96% strains were
CE resistant, and the least level of resistance was observed
with imipenem, a carbapenem. Of them, the strain used in
further interactions with the leaf extract was resistant to CE
(30 mg/disc), which was also resistant to amikacin, cefoper-
azone, ceftazidime, ciprofloxacin, gatifloxacin, gentamicin,
levofloxacin, netillin, ofloxacin, piperacillin, and tobramycin;
by contrast, the strain was sensitive to aztreonam, cefepime,
cefoperazone/sulbactam, and piperacillin/tazobactam at spe-
cific levels, except for imipenem (Table 1). The IZ sizes were
measured from the highest (5000 mg/mL) to the lowestconcentration (9.76 mg/mL) of the leaf extract against P.
aeruginosa. The maximum IZ size recorded was 19.7 mm, and
the minimum recorded size was 8.7 mm (Table 2). A regres-
sion line was drawn with a log10 value of different concen-
trations and the corresponding IZ square values. The line had a
slope of y ¼ 121.6x e 73.3 and the Pearsonian correlation
coefficient (r) of 0.9867 (Fig. 5). As can be noted from the
linear relationship between these two parameters and the high
value of r, the leaf extract had a direct cause-and-effect rela-
tionship with the IZ sizes, due to 10 successive levels of
twofold concentrations of the leaf extract and CE in the
Table 2
IZ values of different concentrations of methanolic leaf extract of Combretum
albidum against MDR Pseudomonas aeruginosa by agar cup method.
Concentration (mg/mL) Log10
concentration
Average
of IZ (mm)
1Z2
5000.0 3.70 19.7 388.1
2500.0 3.40 18.7 349.7
1250.0 3.10 16.7 278.9
625.0 2.80 17.0 289.0
312.50 2.49 15.0 225.0
156.25 2.19 13.7 187.7
78.125 1.89 12.0 144.0
39.06 1.59 9.7 94.1
19.53 1.29 9.3 86.5
9.76 0.99 8.7 75.7
Pearsonian correlation coefficient (r) ¼ 0.9867, between log10 concentration
and IZ square. The experiment was repeated three times and the data of the last
experiment are presented. Average IZ values are average of three readings.
IZ ¼ inhibition zone; MDR ¼ multidrug resistance.
Fig. 5. Regression plot of squares of inhibition zone values and log10 con-
centrations of Combretum albidum leaf extract.
Table 3
Interaction of methanolic leaf extract of Combretum albidum (50 mg/mL) and cef
Combination ratio
C. albidum:CE
C. albidum
of MIC (mg/mL)
CE of MIC
(mg/mL)
10:0a 0.866 d
9:1 0.345 0.00076
8:2 0.307 0.00153
7:3 0.604 0.00519
6:4 0.102 0.00136
5:5 0.186 0.00384
4:6 0.330 0.0104
3:7 0.584 0.02731
2:8 0.386 0.03120
1:9 0.438 0.07897
0:10b d 0.0389
The experiment was repeated three times and data of the last experiment are give
a Combination concentration: 50:0 mg/mL (leaf extract, for the ratio 10).
b Combination concentration: 0:1 mg/mL (leaf extract, for the ratio 0). ANT ¼
IND ¼ indifference; MIC ¼ minimum inhibitory concentration; SYN ¼ synergism
32 M.C. Sahu et al. / Journal of Acute Medicine 4 (2014) 26e37combination proportions used (Table 3). In this study, the leaf
extract level of 50 mg/mL was used in combination with CE
(30 mg/disc) to control the growth of P. aeruginosa in vitro.
The MIC value of the leaf extract was 0.866 mg/mL at the
combination proportion of 10:0 and that of CE was
0.0384 mg/mL at the proportion of 0:10 (leaf extract:CE). The
MIC value of the leaf extract was 0.102e0.866 mg/mL when
combined with the antibiotic in all proportions (10:0 to 0:10),
and the FIC index was 0.118e0.697 in all the cited pro-
portions. An initial synergism was evident with higher pro-
portions of the leaf extract with lower proportions of CE up to
the 5:5 ratio, and the later antagonism was too evident at
reverse ratios, 3:7 to 1:9; but the ratio 6:4 was indifferent (leaf
extract:CE; Table 3). Individual MBC values of the leaf extract
and CE were 4.39 mg/mL and 87.7 mg/mL, respectively,
whereas those of combinations of all ratios (10:0, 9:1, 8:2, 7:3,
6:4, 5:5, 4:6, 3:7, 2:8, 1:9, and 0:10) ranged from 0.33 to
3.07 mg/mL; the FBC value of the leaf extract ranged from
0.08 to 0.70 (Table 4). The MBC value of C. albidum was
4.39 mg/mL when treated alone against the P. aeruginosa,
whereas in different combinations (9:1 to 1:9) with CE, the
values varied from 0.70 to 3.07 mg/mL. In the same way,
when CE was treated alone with P. aeruginosa, the MBC value
was 0.877 mg/mL. However, when CE was combined with
different proportions of the leaf extract, the MBC values
varied from 0.00172 to 0.1777 mg/mL in different combina-
tions. The highest MBC value of the leaf extract in combi-
nation with CE was 3.07 mg/mL at the ratio 7:3 (leaf
extract:CE), whereas at the ratio of 4:6, the MBC value was
the lowest (0.33 mg/mL). The highest MBC value of CE was
at the ratio of 1:9 and the lowest was at the ratio of 9:1. The
FBC values of CE ranged from 0.04 to 2.03, at all ratios from
9:1 to 1:9 (Table 4). The methanolic leaf extract had saponins,
resins, steroids, tannins, glycosides, acidic compounds terpe-
noids, reducing sugars, phenols, carbohydrates, sterols, flavo-
noids, carotenoids, and alkaloids in qualitative phytochemical
analyses, but phlobatannins, lipids or fats, acidic compounds,
and anthraquinones were absent (Table 5).triaxone (1 mg/mL) against Pseudomonas aeruginosa.
FIC of
C. albidum
FIC of CE FIC index Inference
d d d d
0.398 0.019 0.417 SYN
0.354 0.039 0.393 SYN
0.697 0.133 0.83 ANT
0.118 0.34 0.458 SYN
0.214 0.098 0.312 SYN
0.381 0.267 0.648 IND
0.674 0.720 1.394 ANT
0.445 0.802 1.247 ANT
0.505 2.03 2.535 ANT
d d d d
n here.
antagonistic; CE ¼ ceftriaxone; FIC ¼ fractional inhibitory concentration;
. “d” denotes use of either plant extract or antibiotic.
Table 4
MBC and FBC value of leaf extract of Combretum albidum (50 mg/mL) and
ceftriaxone (1 mg/mL).
S. no. Ratio of drug
combination
C. albidum:CE
C. albidum
MBC (mg/mL)
CE
MBC (mg/mL)
FBC
C. albidum
FBC CE
1 10:0a 4.39 d d d
2 9:1 0.78 0.00172 0.18 0.012
3 8:2 0.70 0.00346 0.16 0.04
4 7:3 3.07 0.02632 0.70 0.30
5 6:4 0.512 0.00693 0.12 0.08
6 5:5 0.96 0.01950 0.22 0.22
7 4:6 0.33 0.0104 0.08 0.12
8 3:7 2.96 0.13827 0.67 1.58
9 2:8 1.97 0.158 0.45 1.80
10 1:9 0.986 0.1777 0.22 2.03
11 0:10b d 0.0877 d d
CE ¼ ceftriaxone; FBC ¼ fractional bactericidal concentration;
MBC ¼ minimum bactericidal concentration.
a Combination concentration ¼ 50:0 mg/mL.
b Combination concentration ¼ 0:1 mg/mL.
Table 6
Probit transformation and computations of probit values of both observed and
expected partial lethal ranges for the leaf extract and ceftriaxone during
toxicity studies with lymphocytes, assessed by AO/EB staining.
Concentration Log10 concentration Percent lethality Probit values
Leaf extract concentration (mg/mL)
0 0
50 1.698 23.6 4.2808
25 1.397 17.7 4.0731
12.5 1.096 11.8 3.8150
6.25 0.795 11.8 3.8150
3.125 0.494 5.9 3.4368
Ceftriaxone concentration (mg/mL)
0 0
62.5 1.796 8.7 3.6405
125 2.096 13.1 3.8783
250 2.397 34.8 4.6093
500 2.698 52.2 5.0552
1000 3 60.9 5.2767
Log10 values of concentrations of leaf extract and probits of observed percent
lethality of cell death are plotted in Fig. 6. The cells/mL values are average
hemocytometric cell counts multiplied with average cell
number  16  2500  2, with respect to 0 mg/mL leaf extract or 0 mg/mL
ceftriaxone (3 replicates).
AO/EB ¼ acridine orange/ethidium bromide.
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lymphocytes from human cord blood monitored by the
AO/EB staining method
3.2.1. Leaf extract of C. albidum
Treatment of lymphocytes with different concentrations of
methanolic leaf extract of C. albidum for 24 hours resulted in a
limited decreasing pattern of living cell counts. The number of
dead cells increased a little upon increasing the leaf extract
level from 3.125 to 50 mg/mL. Probit values presented in
Table 6 were used in the ordinate and log10 values of plant
extract concentrations in the abscissa for the construction of
the plot (Fig. 6), from which it was ascertained that for values
of lethal concentration 25 (LC25), the corresponding log10
concentration value was 1.77. Antilog values of the obtained
log10 concentration value were 58.88 mg/mL, which isTable 5
Qualitative phytochemical analysis of leaf extract of Combretum albidum.
S. no. Phytochemical Presence/absence
1 Acidic compounds e
2 Alkaloids þ
3 Anthraquinones e
4 Carbohydrates þ
5 Carotenoids þ
6 Flavonoids þ
7 Glycosides þ
8 Lipids e
9 Phenols þ
10 Phlobatannins e
11 Reducing sugars þ
12 Resins þ
13 Saponins þ
14 Steroids þ
15 Sterols þ
16 Tannins þ
17 Terpenoids þ
“þ” means presence; “e” means absence.regarded as the LC25 value of the leaf extract against human
lymphocytes.
3.2.2. CE
By contrast, the treatment of cells with different concen-
trations of CE for 24 hours of incubation with lymphocytes
resulted in a larger extent of decreasing pattern of living cell
counts compared with that of the leaf extract. The number of
dead cells increased upon increasing the concentration of CE
from 62.5 to 1000 mg/mL. Using probit values (Table 7), the
probit plot was constructed (Fig. 6), from which it was
ascertained that values of LC25 and LC50 corresponding toFig. 6. Percentage lethality values plotted against concentrations of the leaf
extract (Line A) and percentage lethality values plotted against log10 ceftri-
axone concentrations (Line B) in toxicity studies with lymphocytes. Both
straight lines have been fitted by eyes. Extrapolated LC25 value was 58.88 mg/
mL for Line A; the LC25 and LC50 values for Line B were 380.19 741.31 mg/
mL, respectively. LC ¼ lethal concentration.
Table 7
Probit transformation and computations of probit values of both observed
lethal ranges for the leaf extract and ceftriaxone during toxicity studies with
lymphocytes assessed by the MTT assay.
Concentration Log10 concentration Percent lethality Probits values
Leaf extract concentration (mg/mL)
0 0.4 2.3479
3.125 0.494 4.8 3.3354
6.25 0.795 11.4 3.7945
12.5 1.096 10.8 3.7628
25 1.397 15.5 3.9848
50 1.698 22.4 4.2412
Ceftriaxone concentration (mg/mL)
0 0.2 2.1218
62.5 1.796 10.2 3.7298
125 2.096 14.8 3.9550
250 2.397 31.3 4.5126
500 2.698 53.6 5.0904
1000 3.0 69.8 5.5187
Log10 values of plant extract concentrations and probits of observed per-
centage lethality are plotted in Fig. 7. The OD570 values of the MTT assay
were used for computing percent lethal values with respect to 0 mg/mL leaf
extract or 0 mg/mL ceftriaxone (3 replicates).
MTT ¼ 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide;
OD570 ¼ optical density at a wavelength of 570 nm.
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Antilog values of these log10 concentration values were 380.19
and 741.3 mg/mL, respectively, which were the required LC25
and LC50 values of the CE against lymphocytes.3.3. Host-toxicity testing with lymphocytes from human
cord blood monitored by the MTT assayIn the MTT assay, the LC25 value of the leaf extract was
53.70 mg/mL and the LC50 value could not be determined
from the probit plot (Fig. 7), as levels higher than 50 mg/mL
of the extract were not used in the combination with CE.Fig. 7. Probits of lethality percentage values by the MTT assay plotted against
log10 concentrations of the leaf extract (Line A) and ceftriaxone (Line B) in
the toxicity study of lymphocytes. MTT ¼ 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide.Further, the LC25 and LC50 values of CE were 154.88 and
602.56 mg/mL, respectively. Experimentally, the MIC values
were 3.125 mg/mL of leaf extract and 62.5 mg/mL of CE. The
Highest permissive concentration (HPC) and LC100 values
could not be determined for both leaf extract and CE, as these
were considerably higher doses and were not used in the
synergy/antagonistic interaction as well as with lymphocytes.
Probit plots after probit conversions of percentage lethality
values and log10 values of leaf extract and CE concentrations
were constructed (Fig. 7). Thus, the level of 50 mg/mL leaf
extract was a little below the LC25 value of leaf extract,
53.70 mg/mL, compared to the MIC value, 3.125 mg/mL. The
recommended value of CE (i.e., 30 mg/mL) was far less than
its MIC valued62.5 with lymphocytesdduring the MTT
assay. Histograms of LC values of lymphocytes treated with
the AO/EB staining method and MTT assay in toxicity studies
using leaf extract of C. albidum and CE are shown in Fig. 8.
4. Discussion
The study results showed that the methanolic leaf extract of
C. albidum alone at the minimum level (0.866 mg/mL) had a
promising antipseudomonad activity against MDR isolates of
the bacterium MDR P. aeruginosa, whose infectious activities
were well presented in our hospital.23 Further, it was seen that
the leaf extract at the minimum level (0.866 mg/mL) had a
potential effect on the enhancement of the activity of CE at the
0.0389 mg/mL level. The combination of leaf extract and the
antibiotic had a synergistic effect with combination ratios from
9:1 to 5:5; especially, at the ratio of 7:3 (leaf extract:CE), the
highest level of synergism, as found in three repeated exper-
iments, was noticed. The combination ratio of 4:6 had an
indifferent response and the remaining combinations with
decreased levels of leaf extract (with increased levels of an-
tibiotics) had an antagonistic effect against P. aeruginosa. The
FIC indices were from 0.312 to 2.535. The individual MIC
values were 0.102e0.604 mg/mL for C. albidum, and
0.00076e0.07897 mg/mL for CE. These results of in vitroFig. 8. Histograms of lethal concentration values of lymphocytes treated with
the acridine orange/ethidium bromide staining method and MTT assay in
toxicity studies using leaf extract of Combretum albidum and ceftriaxone. AO/
EB ¼ acridine orange/ethidium bromide; MTT ¼ 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide.
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and CE at particular ratios had a possible clinical significance.
The best synergistic effect was obtained at the combination
ratio 5:5, whereas at the ratio 4:6 an indifference was noticed,
and at three successive lower levels, 3:7 to 1:9, antagonism
was recorded. This signifies the importance of the leaf extract
in combinational proportions in this study. At higher levels of
the leaf extract in combinations, that is, from 9:1 to 6:4, there
was a limited antibiotic dosage to be energized by the leaf
extract in the combined application, as there were higher FIC
indices. This clearly indicated that the plant extract had a
synergistic effect with the action of the antibiotic CE. The
spectrum of chemical constituents of C. albidum is such a
diverse mixture that MDR P. aeruginosa should not overcome
the leaf extract, as expected. The antibiotic CE was found to
control the bacterial growth in higher doses in vitro, and
therefore, it could be used at higher doses in vivo. However,
many side effects are possible when the antibiotic is used at
higher doses. Furthermore, host toxicity due to crude phy-
toextracts is also documented.38 Therefore, the study of
toxicity using animal models remains to be an essential cor-
ollary. However, this work epitomizes that even when a lower
level of a moribund antibiotic is administered in combination
with a moderate dose of the leaf extract of C. albidum, a
nontoxic plant known from ethnobotanical reports,25 the MDR
pathogen can be controlled by avoiding various nontarget side
effects of the antibiotic that would arise due to its use in higher
doses. This conclusion is substantiated by nontoxic levels of
the leaf extract on human lymphocytes, that is, the LC25 values
were obtained in the study.
Usually, for the control of P. aeruginosa, the combination
therapy involves the use of a b-lactam and an aminoglycoside
or a chloroquinol.39 In literature, in vitro synergy rates for
aztreonam (a b-lactam) combined with a fluoroquinolone
against Gram-negative bacteria are available, but those are not
comparable here, because of the variation in the microbial test
method.40 However, the combination of a leaf extract and the
antibiotic provided a larger spectrum of antimicrobial effect on
MDR P. aeruginosa, which should concomitantly prevent the
emergence of MDR pathogens. Combinational drugs are often
recommended for the control of pathogens and to have greater
efficacy in the treatment of infection, if an attack of resistant
tubercle bacillus mutants has not been confirmed.1 Studies on
combined applications of a plant extract and an antibiotic are
rare in literature.22,41,42 In vitro combined effects of erythro-
mycin and the methanolic leaf extract of the plant Euphorbia
hirta against the clinically isolated Gram-positive bacterium
Staphylococcus aureus were described using the checkerboard
technique. The MIC value of the plant extract alone was
25 mg/mL and that of the antibiotic alone was 0.005 mg/mL;
however, when used in combination (9:1, 8:2, 7:3, 6:4, 3:7,
2:8, and 1:9) the extract and the drug had a synergistic effect.
However, indifference was recorded at 5:5 and 4:6 combina-
tions.41 Further, in vitro synergistic actions of four essential
oils of plants individually, Aniba rosaeodora, Melaleuca
alternifolia, Origanum vulgare, and Pelargonium graveolens,
had been described with the antibiotic gentamicin againstAcinetobacter baumannii and 14 strains of Gram-positive and
Gram-negative bacteria, with an FIC index of 0.11 using the
checkerboard dilution method,42 as done here. In another
study, synergism between the antibiotic ampicillin and the
methanolic extract of lichen Ramalina farinacea against
clinical isolates of S. aureus was demonstrated at combination
ratios of 9:1, 8:2, 6:4, 5:5, 4:6, and 3:7.22 In a Chinese study,
both aspirin and crude extract of Ginkgo biloba reduced su-
peroxide anion in human coronary artery endothelial cells in a
dosage-dependent manner; combinational administration of
aspirin and the extract showed synergistic effects with the
inhibition of reactive oxygen species production.19
Moreover, methanol is routinely used as the solvent in the
protocol of bioassay-guided fractionation of a crude phy-
toextract, for its capability to extract polar, moderately polar as
well as nonpolar compounds from crude plant extracts
holisticallyda characteristic dearth in most other organic
solvents. Thus, methanol serves to a great extent the isolation
of a majority of active phytocompounds of specific interest
from a crude plant extract. It is anticipated that coteries of
pharmacognosy, pharmacology, and pharmaceutics could take
up the work on isolation and characterization of pure phyto-
compounds of C. albidum and their standardization as anti-
microbials, singularly or in a combination as shown here.
Because bacterial genomes are changing rapidly or rather
dramatically to win over newer antibiotics in addition to being
peripatetic, there is a fear of precipitation of future public
health episodes in the unhygienic milieu of urban slum ghet-
tos, wherein MDR bacterial pathogens insinuate and thrive
well. In this condition, a combination therapy using a mori-
bund antibiotic with a phytodrug could be cost effective. A
pejorative attitude on phytodrugs would be a dislogistic
approach to the plethora of natural source of drugs.
This work clearly demonstrated that nontoxic levels of
methanolic extract of a nontoxic plant could have a synergistic
effect along with an antibiotic, which was initially ineffective
against the MDR isolates of an infamous pathogenic bacte-
rium. Thus, similar work on using phytoextracts in rejuve-
nating the actions of moribund antibiotics that are unable to
inhibit similar grievous pathogens could benefit clinical
application of such drugs. The LC25 value of the leaf extract
was 58.88 mg/mL with human lymphocytes, and the level of
50.0 mg/mL was used in the synergistic study. The toxicity
study clearly corroborated that the leaf extract was nontoxic to
human lymphocyte cultures. Thus, such studies could possibly
help in controlling the growth of MDR pathogens that are
capable of precipitating episodes in public health. Because
phytocompounds such as phlobatannins, lipids or fats, acidic
compounds, and anthraquinones were absent in the leaf
extract, these are supposed to have no contribution to the
recorded synergistic action with CE in the control of MDR P.
aeruginosa. This plant could be used as a part of integrative
medicine for the pathogen, with mainstream antimicrobials,
after due pharmacological checkups with test animals, despite
its ethnic use as an edible crude medicine by rural and tribal
people. This work is a scientific in vitro validation of a plant
used by an Indian tribal society as a herbal medicine.
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